{"entity":{"id":"taiho","kind":"company","name":"Taiho Pharmaceutical (Otsuka)","aka":[],"tldr":"Japanese oncology company behind futibatinib (Lytgobi) for bile duct cancer and the chemotherapy Lonsurf; acquired the ADC linker company Araris in 2025.","summary":"Taiho Pharmaceutical, the Tokyo-based oncology arm of Otsuka, is the company behind futibatinib, sold as Lytgobi, for bile duct cancer, and the chemotherapy Lonsurf, and in 2025 it acquired the antibody-drug conjugate linker company Araris Biotech. Futibatinib was approved in 2022 on the FOENIX-CCA2 trial for FGFR2-altered cholangiocarcinoma, Lonsurf, or trifluridine and tipiracil, is used in colorectal and gastric cancer with TAS-102 combinations under study, and OnCo also links Taiho to S-1, the tegafur, gimeracil and oteracil combination used in Asia. The Araris purchase signals a move from small molecules into ADCs. Whether a chemotherapy-rooted company can build a competitive ADC pipeline from an acquired linker platform is the open question. Futibatinib and Araris have their own pages.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.taiho.co.jp/en/"}],"tags":[],"related":[],"cancers":["cholangiocarcinoma","colorectal"],"sections":["targeted-therapy","adcs"],"technologies":[],"targets":[],"drugs":["futibatinib"],"companies":["araris"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.taiho.co.jp/en/","investors":[],"funding":[]},"route":"/companies/taiho/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"futibatinib","kind":"drug","name":"Futibatinib","route":"/drugs/futibatinib/"},{"id":"tegafur-gimeracil-oteracil","kind":"drug","name":"Tegafur, gimeracil and oteracil (S-1)","route":"/drugs/tegafur-gimeracil-oteracil/"}],"company":[{"id":"araris","kind":"company","name":"Araris Biotech (Taiho)","route":"/companies/araris/"},{"id":"otsuka","kind":"company","name":"Otsuka Pharmaceutical","route":"/companies/otsuka/"}],"trial":[{"id":"ascertain-v","kind":"trial","name":"ASCERTAIN-V","route":"/trials/ascertain-v/"},{"id":"foenix-cca2","kind":"trial","name":"FOENIX-CCA2","route":"/trials/foenix-cca2/"},{"id":"jaspac-01","kind":"trial","name":"JASPAC 01","route":"/trials/jaspac-01/"},{"id":"recourse","kind":"trial","name":"RECOURSE","route":"/trials/recourse/"},{"id":"tapur","kind":"trial","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","route":"/trials/tapur/"}],"paper":[{"id":"paper-mayer-recourse-tas-102-nejm-2015","kind":"paper","name":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer (RECOURSE)","route":"/key-papers/paper-mayer-recourse-tas-102-nejm-2015/"},{"id":"paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023","kind":"paper","name":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT)","route":"/key-papers/paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023/"}]}}